Trial
NCT02978443
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Georgetown University
Collaborators
Melanoma Research Foundation Breakthrough Consortium; Bristol-Myers Squibb; University of Colorado, Denver; University of California, San Francisco; Vanderbilt University; Columbia University; University of Pittsburgh; Yale University; M.D. Anderson Cancer Center; H. Lee Moffitt Cancer Center and Research Institute; Memorial Sloan Kettering Cancer Center; Northwestern University; Dana-Farber Cancer Institute
Condition
Acral Lentiginous Melanoma
Intervention
Nivolumab
Why stopped
Lack of Enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-04